Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy

Sridhar Shankar, S. K. Dundamadappa, A. R. Karam, R. M. Stay, E. Van Sonnenberg

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) account for the majority of gastrointestinal mesenchymal tumors. Recent advances in treatment using the molecular targeting agent imatinib mesylate have shown startling response rates and variegated imaging findings. We present the various imaging appearances of GIST on computed tomography (CT) and magnetic resonance imaging (MRI), both before and after treatment.

Original languageEnglish (US)
Pages (from-to)837-844
Number of pages8
JournalActa Radiologica
Volume50
Issue number8
DOIs
StatePublished - Oct 21 2009

Fingerprint

Gastrointestinal Stromal Tumors
Tomography
Magnetic Resonance Imaging
Therapeutics
Neoplasms
Imatinib Mesylate

All Science Journal Classification (ASJC) codes

  • Radiological and Ultrasound Technology
  • Radiology Nuclear Medicine and imaging

Cite this

Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy. / Shankar, Sridhar; Dundamadappa, S. K.; Karam, A. R.; Stay, R. M.; Van Sonnenberg, E.

In: Acta Radiologica, Vol. 50, No. 8, 21.10.2009, p. 837-844.

Research output: Contribution to journalReview article

Shankar, Sridhar ; Dundamadappa, S. K. ; Karam, A. R. ; Stay, R. M. ; Van Sonnenberg, E. / Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy. In: Acta Radiologica. 2009 ; Vol. 50, No. 8. pp. 837-844.
@article{22dcec37289545808db68307780ccb37,
title = "Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy",
abstract = "Gastrointestinal stromal tumors (GISTs) account for the majority of gastrointestinal mesenchymal tumors. Recent advances in treatment using the molecular targeting agent imatinib mesylate have shown startling response rates and variegated imaging findings. We present the various imaging appearances of GIST on computed tomography (CT) and magnetic resonance imaging (MRI), both before and after treatment.",
author = "Sridhar Shankar and Dundamadappa, {S. K.} and Karam, {A. R.} and Stay, {R. M.} and {Van Sonnenberg}, E.",
year = "2009",
month = "10",
day = "21",
doi = "10.1080/02841850903059423",
language = "English (US)",
volume = "50",
pages = "837--844",
journal = "Acta Radiologica",
issn = "0284-1851",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy

AU - Shankar, Sridhar

AU - Dundamadappa, S. K.

AU - Karam, A. R.

AU - Stay, R. M.

AU - Van Sonnenberg, E.

PY - 2009/10/21

Y1 - 2009/10/21

N2 - Gastrointestinal stromal tumors (GISTs) account for the majority of gastrointestinal mesenchymal tumors. Recent advances in treatment using the molecular targeting agent imatinib mesylate have shown startling response rates and variegated imaging findings. We present the various imaging appearances of GIST on computed tomography (CT) and magnetic resonance imaging (MRI), both before and after treatment.

AB - Gastrointestinal stromal tumors (GISTs) account for the majority of gastrointestinal mesenchymal tumors. Recent advances in treatment using the molecular targeting agent imatinib mesylate have shown startling response rates and variegated imaging findings. We present the various imaging appearances of GIST on computed tomography (CT) and magnetic resonance imaging (MRI), both before and after treatment.

UR - http://www.scopus.com/inward/record.url?scp=70350025423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350025423&partnerID=8YFLogxK

U2 - 10.1080/02841850903059423

DO - 10.1080/02841850903059423

M3 - Review article

VL - 50

SP - 837

EP - 844

JO - Acta Radiologica

JF - Acta Radiologica

SN - 0284-1851

IS - 8

ER -